Forsinkede kurser. Sist oppdatert: tirsdag 23. april  

15/01-2019 09:38:05: (NATTO.OAX) Kaydence Pharma - Successful completion of Pre-IND meeting with FDA

Oslo, Norway (15 January 2019) - Kaydence Pharma AS, the development stage
pharmaceutical company spun-out of NattoPharma in 2017, reports today that it
has successfully completed a pre-IND (Investigational New Drug) meeting with the
US Food and Drug Administration (FDA). At the meeting, the FDA addressed
questions regarding key components of the planned IND application and the
clinical/regulatory pathway for MQ7, Kaydence Pharma's novel drug candidate for
the treatment of arterial stiffness in stable renal transplant recipients with
subclinical vitamin K deficiency.

"The continued positive momentum in the Kaydence Pharma development plan is very
encouraging and validates the strategic decision to spin the activity out of
NattoPharma's ordinary supplement business in 2017. This decision ensures that
Kaydence continues to have both the correct focus and attention from competent
people to succeed. NattoPharma is very enthusiastic about this project and has
great faith in the future potential for a pharmaceutical drug based on the
extensive clinical understanding that NattoPharma has developed over the last 10
years of working with MK-7." said Kjetil Ramsøy, CEO of NattoPharma.

The press release issued by Kaydence Pharma is attached to this announcement for
further reading.

X X X

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the exclusive international supplier of
MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK
-7) with guaranteed actives and stability, clinical substantiation, and
international patents granted and pending; and now the new MenaQ7® Full
Spectrum, which delivers menaquinones 6, 7 and 9. The company has a multi-year
research and development program to substantiate and discover the health
benefits of Vitamin K2 for applications in the marketplace for functional food
and dietary supplements. With a global presence, the company has a North
American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D
Ltd. in Cyprus. For more information, visit www.nattopharma.com or
www.menaq7.com.

For more information, please contact:

Kjetil Ramsøy, NattoPharma Chief Executive Officer

E-mail: kjetil.ramsoy@nattopharma.c

Ekstern link: https://newsweb.oslobors.no/message/467475

Nyheten er levert av OBI.